PLx Pharma Inc. Common Stock
PLXP
PLXP was delisted on the 12th of April, 2023.
40 hedge funds and large institutions have $4.11M invested in PLx Pharma Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 11 increasing their positions, 13 reducing their positions, and 9 closing their positions.
15% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 13
17% less funds holding
Funds holding: 48 → 40 (-8)
78% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 9
79% less capital invested
Capital invested by funds: $19.3M → $4.11M (-$15.2M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SGCA
Steel Grove Capital Advisors
Memphis,
Tennessee
|
+$270K |
| 2 |
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO)
Austin,
Texas
|
+$92.4K |
| 3 |
OBGC
O'Brien Greene & Co
Media,
Pennsylvania
|
+$65.8K |
| 4 |
SRC
Shufro Rose & Co
New York
|
+$37.3K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$22K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
-$1.03M |
| 2 |
MP
MSD Partners
New York
|
-$842K |
| 3 |
Morgan Stanley
New York
|
-$644K |
| 4 |
Two Sigma Investments
New York
|
-$171K |
| 5 |
D.E. Shaw & Co
New York
|
-$157K |
PLXP Hedge Fund Activity: Q3 2022 in Review
40 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in PLx Pharma Inc. Common Stock (PLXP) for Q3 2022, worth a combined $4.11M — down 79% from $19.3M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of PLXP and 2 opened new positions — a net loss of 7 holders — while 13 trimmed existing stakes and 11 added.
The largest buyer was Steel Grove Capital Advisors, adding an estimated $270K. The largest seller was GW&K Investment Management, exiting entirely with an estimated $1.03M sold.
- 40 institutional investors held PLx Pharma Inc. Common Stock (PLXP) as of Q3 2022, down from 48 in Q2 2022.
- Funds reported $4.11M of PLx Pharma Inc. Common Stock stock for Q3 2022, down 79% quarter-over-quarter.
- 2 funds opened new PLx Pharma Inc. Common Stock positions in Q3 2022 and 9 closed out, a net change of -7 holders.
- The largest PLx Pharma Inc. Common Stock buyer in Q3 2022 was Steel Grove Capital Advisors, an estimated $270K added.
- The largest PLx Pharma Inc. Common Stock seller in Q3 2022 was GW&K Investment Management, an estimated $1.03M sold.
Based on aggregated 13F filings for Q3 2022.